JMP WEEKLY REPORT

03-07 NOV 2025

Weekly Trade Commentary

- Last week saw 4 stocks traded on the local market with a total trading value of K1,453.352.60.
- BSP traded 7,738 shares, closing steady at K24.00.
- KSL traded 31,072 shares. Closing lower form the previous week at K3.80.
- STO managed to trade 53,905 shares but closed 50t lower at K20.00.
- Lastly, CCP traded 11,217 shares lower by 2t at K4.63.

STOCK	WEEKLY VOLUME	CLOSING PRICE	VALUE	BID	OFFER	CHANGE K	CHANGE %
BSP	7,738	24.00	170,232.05	24.00	24.20	0.40	0.02
KSL	31,072	3.80	118,078.84	3.80	3.85	(0.01)	(0.26%)
STO	53,905	20.00	1,113,107.00	-	20.50	(0.50)	(2.44%)
NEM	-	181.00	-	-	-	-	-
KAM	-	1.90	-	1.90	-	-	-
NGP	-	1.35	-	1.35	-	-	-
CCP	11,217	4.65	51,934.71	-	4.64	(0.02)	(0.43%)
CPL	-	0.45	-	0.40	0.50	-	-
SST	-	50.00	-	-	50.00	-	-
Total	**103,932**		**1,453,352.60**				(1.74%)



Key Takeaways

- Market Announcement: KSL - Strategic Investment and Partnership with NiuPay
https://www.pngx.com.pg/wp-content/uploads/2025/11/2025-11-03-KSL-Strategic-Investment-and-Partnership-with-NiuPay.pdf

- Market Announcement: NEM Filing
https://www.pngx.com.pg/wp-content/uploads/2025/11/2025-11-04-NEM-Form-144-as-filed-Bruce-Brook.pdf
https://www.pngx.com.pg/wp-content/uploads/2025/11/2025-11-04-NEM-Form-144-as-filed-Tom-Palmer.pdf
https://www.pngx.com.pg/wp-content/uploads/2025/11/2025-11-04-NEM-Form-4-as-filed-Natascha-Viljoen.pdf
https://www.pngx.com.pg/wp-content/uploads/2025/11/2025-11-6-NEM-Form-4-as-filed-Tom-Palmer.pdf
https://www.pngx.com.pg/wp-content/uploads/2025/11/2025-11-6-NEM-Form-4-as-filed-Bruce-Brook.pdf
https://www.pngx.com.pg/wp-content/uploads/2025/11/2025-11-6-NEM-Form-4-as-filed-Brian-Tabolt.pdf

- Market Announcement: CPL - Appendix-10B-Notice-of-Change-In-Directors-or-CEOs-Interests
https://www.pngx.com.pg/wp-content/uploads/2025/11/2025-11-04-CPL-Appendix-10B-Notice-of-Change-In-Directors-or-CEOs-Interests-CPL.pdf

- CPL – Insider Trading Policy – Oct 2025
https://www.pngx.com.pg/wp-content/uploads/2025/11/2025-11-04-CPL-Insider-Trading-Policy-Oct-2025.pdf

- Market Announcement: STO - Santos prices US$1 billion 10-year US 144A-Reg S bond
https://www.pngx.com.pg/wp-content/uploads/2025/11/2025-11-06-STO-Santos-prices-US1-billion-10-year-US-144A-Reg-S-bond.pdf

Weekly Yield Chart

STOCK	NUMBER OF ISSUED SHARES	MARKET CAP	2023 INTERIM DIV	2023 FINAL DIV	2024 INTERIM DIV	2024 FINAL DIV	2025 INTERIM DIV	Yield % LTMª
BSP	467,219,979	11,213,279,496	K0.370	K1.060	K0.450	K1.210	K0.500	7.13%
KSL	287,949,279	1,094,207,260	K0.100	K0.160	K0.106	K0.155	K0.126	7.39%
STO	3,247,772,961	64,955,459,220	K0.310	K0.660	K0.506	K0.414	K0.559	4.87%
NEM*	-	-	-	-	-	-	-	-
KAM	50,693,986	96,318,573	K0.120	-	K0.200	-	K0.250	23.68%
NGP	45,890,700	61,952,445	K0.030	-	K0.040	K0.120	K0.040	11.85%
CCP	307,931,332	1,431,880,694	K0.110	K0.130	K0.120	K0.121	K0.121	5.20%
CPL	206,277,911	92,825,060	K0.050	-	-	-	-	-
SST	31,008,237	1,550,411,850	K0.350	K0.600	K0.400	K0.300	K0.400	1.40%
Total		**80,496,334,598**						**5.18%**

** aLTM = Last Twelve Months. We have calculated yields based on most recently declared interim and final dividends.*

** NEM pays quarterly dividends. We have added last 4 payments at current FX rates.*

** NEM has been excluded from Market-wide yield calcs.*



The Dividend Yield Formula

$$\text{Dividend Yield} = \frac{\text{Annual Dividends Per Share}}{\text{Current Share Price}} \times 100$$

Dividend yield - is calculated by dividing a company's annual dividends per share by its current share price and expressing the result as a percentage.

BANK OF PAPUA NEW GUINEA

Domestic Markets Department - Money Markets Operations Unit

Auction Number: **05 NOV-25 / GOI / Government Treasury Bill**

Settlement Date: **07-Oct-25**

Amount on Offer: K276.780 million

TERMS	ISSUE ID 2025 / 63	ISSUE ID 2025 / 91	ISSUE ID 2025 / 4741 182	ISSUE ID 2025 /4700 273	ISSUE ID 2025 / 4743 364	TOTAL
Weighted Average Yield	0.000	0.00%	7.23%	0.00%	7.21%	
Amount on offer Kina Million	0.000	0.000	20.000	50.000	306.780	376.780
Bids Received Kina Million	0.00	0.000	48.300	65.120	479.100	592.520
Successful Bids Kina Million	0.00	0.000	38.300	0.000	396.300	434.600
Overall Auction OVER-SUBSCRIBED by	0.00	0.000	28.300	15.120	172.320	215.740

What we have been reading

By: Bell Potter – Monthly Bell Nov 2025

AUSTRALIAN EQUITY STRATEGY- HOLD NOW, BUY ON WEAKNESS

Paul Basha, Strategist

This has been a grudging rally. Outside of a recent step up in resource earnings, market earnings in Australia have been flat-to-down while multiples keep stretching. That leaves prices fragile to narrative shocks even as pullbacks are bought quickly. We expect that investors continue to buy the dip until the story genuinely changes. If a catalyst lands however, the first leg lower is usually fast and mechanical.

We're not calling a downturn, but risks of a US induced correction have risen, we see three US air pocket triggers: **no policy cushion** (sticky inflation keeps rates higher-for-longer than markets price), **narrow leadership** (an AI bellwether wobble cracks the soft-landing + AI story), and credit cockroaches (small spread moves spark outsized equity selling, signaling tight positioning and thin buffers). Any of these could trigger a fast, multiple-led sell-off that Australia would participate strongly in.

We highlight two high quality stocks our analysts rate HOLD on valuation. In an air-pocket we'd expect multiples to compress while earnings stay comparatively resilient versus sector peers, creating buy-on-weakness set-ups like April this year and August 2024. Assuming no change to the underlying thesis, the price reset is the opportunity.

Figure 1: ASX valuations have moved higher with US equities even though earnings growth have been flat to negative

Source: Refinitiv

Pro Medicus (PME) – Best in class

PME sits at the top of the ASX quality stack. Revenue and earnings keep stepping higher, helped by a contract mix that's getting larger and longer. Renewal dynamics are exceptional: every material renewal has come back at better terms, and most agreements embed an ~80% usage floor, which leaves built-in upside as scan volumes grow. Margins remain 70%+ because this is pure software with tight opex and very sticky customers across tier-one hospitals and imaging networks. The industry backdrop is constructive; imaging volumes and enterprise standardization are structurally rising, and PME is outgrowing the sector.

The channel is broadening as well as deepening. The Authority to Operate (ATO) in the US federal system (Veterans Affairs) is an important and difficult credential to secure and while it doesn't guarantee wins, it opens doors across a large ecosystem and turns security compliance into a sales asset. Internationally, the first EU deal in years was signed and while small in dollars it is useful as a reminder and a proof point that the playbook works across regions.

The product story is now a platform story. PME is moving beyond radiology into cardiology and pathology, giving hospitals a single viewer and workflow across modalities; it's a cleaner value proposition for CIOs that want fewer vendors and simpler integrations. University partnerships are a smart way to pull AI into production, rather than trying to acquire or build the technology from scratch. Cloud deployments keep scaling, which matters for speed of implementation and for attaching the full stack over time.

Bell Potter view: this is one of the highest-quality names on the market. We expect that PME's revenue growth re-accelerates above 30%+ with margins expanding off an already high base as full-stack/cloud deployments and renewal pricing flow through. The P/E steps down each year as earnings compound, though from a very high starting point, with the stock remaining sensitive to multiple compression in a risk-off. HOLD now, Buy on weakness.

Figure 2: PME earnings for forward years are always too conservative, with forecasts revised up every year



Source: Visible Alpha

TechnologyOne (TNE) – PLUS one

TechnologyOne is a high-quality Australian SaaS name with a wide moat in public sector ERP. It serves more than a thousand customers across government, education, health and financial services, with deep integration and long contract cycles that keep switching costs high. The SaaS transition is done; recurring revenue is the engine. Annualized recurring revenue (ARR) passed the $500m mark in 1H25 and net revenue retention sat around 118%, consistent with the 115–120% ambition. The combination of sticky customers plus upsell underpins a credible path toward the FY30 scale targets. Australia remains the base, but higher education in the UK is a real runway as universities standardize on cloud ERP.

The AI strategy adds another leg. The company has recently launched PLUS, an agentic AI layer that sits across the ERP suite, letting users query and execute tasks in natural language against their own data. Thirteen of nineteen existing products (with PLUS being the 20th in the stable) have been AI-enabled to improve usability and data sharing. The go-to market is sensible: AI enhancements come as part of existing subscriptions with a capped number of free interactions, then per-interaction charges; PLUS, itself is a paid subscription with a conversation cap and extra-use fees beyond that. That model should drive higher attach, support net revenue retention (NRR), and nudge margins toward the 35%+ target, without demanding a wholesale change in customer behavior.

Bell Potter view:

Execution has been consistent. EPS has compounded at ~17% over five years, with ~20% growth expected for FY25 and ~21% for FY26. R&D investment of roughly 20–25% of revenue funds a steady cadence of product launches, now with AI in the foreground. Management's FY30 ambitions (including $1bn+ ARR) look high but achievable. Our analyst is currently more bullish than management on the out-years (revenue and margin trajectory), yet even on those numbers the valuation remains full. The stock can grow into its multiple, but at today's settings the PEG sits above 4, which we view as too rich for fresh money. The business quality is not in question: long-dated contracts, high NRR, clear AI monetization paths, and growing both domestically and globally. HOLD now, Buy on weakness.

Figure 3: TNE has consisent earnings growth of ~20% over FY26-28 helping it de-rate over time



Source: Bell Potter Research

Benny Takin
Equities Trader
(benny.takin@jmpmarkets.com)
(+675 7001 9121/320 0240)
JMP Securities Limited
Level 3, ADF Haus, Musgrave Street
PO Box 2064
Papua New Guinea